Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Times cited: 608
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
The New England journal of medicine.
Times cited: 1388